Market open · Delayed intraday data · 12:01 PM ET
Last update: Sep 14, 2026, 11:53 AM ET
Hims & Hers Health, Inc.
12.8% on Aug 19, 2026

Why Hims & Hers Health, Inc. (HIMS) Stock Rose 12.8% on Aug 19, 2026

The clearest new catalyst: CEO defense of FTC lawsuit allegations.

Researched by BestStocks Market Desk · Published Aug 19, 2026
Prior close
$27.39
Aug 19, 2026 close
$31.09
Change
+$3.70
+13.51%
Rel. volume
1.2×
19.9M shares

Why did HIMS stock rise?

Hims & Hers rallied 12.8% on August 19, 2026, driven primarily by CEO Andrew Dudum's appearance on CNBC to defend the company's digital health model against recent FTC lawsuit allegations and to signal potential price reductions for GLP-1 treatments. The move was amplified by short covering, as the stock recovered from recent weakness tied to high short interest near 32% of float.

  • CEO defense of FTC lawsuit allegations: CEO Andrew Dudum appeared on CNBC to push back against a recent FTC lawsuit, defending the company's digital health and billing practices and easing investor regulatory concerns.
  • GLP-1 pricing outlook: Dudum signaled potential price reductions for out-of-pocket GLP-1 treatments, alleviating margin anxiety among investors.
  • Short covering: High short interest near 32% of float helped fuel sharp upside momentum as sentiment briefly turned positive.
Note: The published narrative stated no company-specific catalyst was found, but the confirmed move was driven by CEO Andrew Dudum's CNBC appearance defending against FTC allegations and signaling GLP-1 pricing relief.
Researched from primary and established sources on Aug 20, 2026.

Initial detection

BestStocks first flagged HIMS intraday on Aug 19, 2026; this analysis was finalized after the close using the confirmed +12.8% session move and additional catalyst research.

Show the initial intraday note
Material / Earnings+12.8%high confidence

Hims & Hers Health, Inc. (HIMS) moved +12.85% from $27.55 to $31.09 on 2026-08-19. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.7x the 5-day average, modestly elevated.

Source: daily_prices:fmp_change_percent

What to watch next: Monitor for earnings on 2026-11-02 and compare reported EPS to the $0.12 consensus estimate.

Frequently asked questions

Why did Hims & Hers Health, Inc. (HIMS) stock rise on Aug 19, 2026?

Hims & Hers rallied 12.8% on August 19, 2026, driven primarily by CEO Andrew Dudum's appearance on CNBC to defend the company's digital health model against recent FTC lawsuit allegations and to signal potential price reductions for GLP-1 treatments. The move was amplified by short covering, as the stock recovered from recent weakness tied to high short interest near 32% of float.

How much did HIMS stock rise on Aug 19, 2026?

HIMS rose 12.8% during the Aug 19, 2026 trading session.

What were the main drivers behind HIMS's move?

CEO defense of FTC lawsuit allegations; GLP-1 pricing outlook; Short covering.

This is an archived analysis of HIMS's Aug 19, 2026 session.
See HIMS's latest changes →
Educational research tool — not personalized investment advice. Figures reflect the Aug 19, 2026 session as first analyzed.